- Article
Cardiovascular diseases remain a major global health challenge, highlighting the need for accessible, intelligent, and real-time cardiac monitoring solutions. This paper presents Moroccan VitaTrack GeoMed, a patented Made-in-Morocco 12-lead ECG monitoring prototype integrating embedded signal acquisition, artificial intelligence, real-time visualization, and screening support. The proposed framework combines ECG preprocessing, a new hybrid CNN–Transformer architecture for local morphological feature extraction and long-range temporal dependency modeling, and an ensemble-based meta-classification module designed to improve prediction robustness under practical operating conditions. The proposed classification framework was retrospectively evaluated using 7536 12-lead ECG recordings from a publicly available dataset, covering nine ECG categories. Across ten experimental runs, the framework achieved a micro-F1 of 91.76 ± 0.23%, a macro-F1 of 87.35 ± 0.19%, and a micro-AUPRC of 96.46 ± 0.13%. The highest F1-scores were obtained for SR (95.40 ± 0.22%) and SB (95.14 ± 0.23%). AFL, ST, AF, and TWC achieved F1-scores between 86.72 ± 0.39% and 90.80 ± 0.42%, while MI, SA, and MCA showed more moderate performance at 79.42 ± 0.46%, 80.37 ± 0.48%, and 79.94 ± 0.67%, respectively, possibly due to overlapping ECG patterns and class heterogeneity. Separately from this retrospective algorithmic evaluation, the framework was integrated into the Moroccan VitaTrack GeoMed prototype and assessed through a one-month preliminary technical feasibility study involving a single healthy volunteer (the principal author). A total of 42 repeated ECG recording sessions were conducted under six monitoring conditions, of which 38 produced analyzable recordings, corresponding to a technical session consistency rate of 90.5%. Comparison with a conventional 12-lead ECG system demonstrated relative measurement differences below 3% and a signal correlation coefficient of 0.93. These findings support the preliminary engineering feasibility of the integrated platform for real-time ECG acquisition, processing, visualization, and screening-support functionality. Importantly, the reported classification metrics were obtained from retrospective database recordings and do not represent diagnostic performance on pathological ECG signals acquired directly using the prototype. Further prospective clinical studies involving independent participants and patients with documented cardiac abnormalities are required to establish diagnostic validity, clinical utility, and generalizability before routine clinical use.
14 November 2026






